September 10th, 2024 (Shanghai) — We are glad to announce that Taehoon Lee, the Chief Executive Officer of Novacell Technology Inc., will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
About Novacell Technology Inc.
Novacell Technology Inc. is a biotech company focusing on the development of immunotherapeutic agents for chronic inflammatory and autoimmune diseases. Novacell Technology sets the company aside from other companies in the inflammatory diseases treatment category through methodology, pro-resolution strategy. The pro-resolution reinforcement strategy is driving a paradigm shift in the treatment of inflammatory diseases due to reduced drawbacks and increased advantages. The methodology revolves around targeting of FPR2 (Formyl Peptide Receptor 2) – a prototypical pro-resolving GPCR with Lipoxin-A4 as a ligand – with PEPTIROID (PEPTIde Resolving Overload of Inflammatory/Immune Diseases), Novacell Technology’s own peptide product line.
The company’s current main targets with first generation PEPTIROID are atopic dermatitis and dry-eye disease, which are in Phase II and Phase I clinical trials, respectively. These conditions significantly lower the quality of life (QOL) for those affected, and Novacell technology intends to provide a novel treatment option that is topical and safe for long-term treatment, ultimately improving QOL. The second generation PEPTIROID is under lead optimization stage, demonstrating higher activity against FPR2, along with higher stability and selectivity. Novacell technology plans to broaden the administration route using the second generation PEPTIROID to injectable, inhaled, oral, and other forms, targeting multiple immune mediated diseases such as ulcerative colitis, psoriasis and asthma. Novacell technology is attending ACCESS CHINA in interest of searching for licensing-out or co-development partners.
About the speaker
Taehoon Lee is a biotech professional with more than twenty years of experience in the field of biological sciences. Taehoon has got the bachelor’s degree at biological science department of KAIST, one of the most prestigious science/technology-oriented universities in Korea, and a doctorate degree of cellular signal transduction from POSTECH, another renowned university in the field of biotechnology. For further empowerment of his knowledge of biological sciences, Taehoon went to Emory university medical school for postdoctoral fellowship, and then he came back to POSTECH as a postdoctoral researcher in developmental genetics.
During many years of studies in biological sciences, Taehoon brewed up his ideas on formyl peptide receptor, which ended up with Novacell’s PEPTIROID product line targeting formyl peptide receptors. Taehoon, as a CEO of Novacell Technology with deep biological background of the formyl peptide receptors, has led the production of PEPTIROID pipeline, completion of Phase I clinical trial of PEPTIROID on atopic dermatitis, licensing-out of PEPTIROID on dry-eye disease etc. Taehoon intends to further increase the pipeline for immune-mediated diseases for bringing the disease under control.
About ACCESS CHINA Partnering Forum
ACCESS CHINA Partnering Forum – Autumn Virtual Showcase is scheduled to be held on September 24th to 25th, and 27th, 2024, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, audience can have access to innovative pharma and healthcare products from worldwide.
Conference Name: ACCESS CHINA Partnering Forum
Date & Time: Sep 24 – 25 (live), and 27 (VoD) 2024, China time
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 500+ participants Online; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs
View more information at https://biotochina.org/
REGISTER
To Register for ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 